Related Experiment Video

Updated: Jun 13, 2026

Strategy for Biobanking of Ovarian Cancer Organoids: Addressing the Interpatient Heterogeneity across Histological Subtypes and Disease Stages
08:26

Strategy for Biobanking of Ovarian Cancer Organoids: Addressing the Interpatient Heterogeneity across Histological Subtypes and Disease Stages

Published on: February 23, 2024

Refocusing the war on cancer: the critical role of personalized treatment

Anil Potti1, Richard L Schilsky, Joseph R Nevins

  • 1Duke Institute for Genome Sciences and Policy, Duke University Medical Center, Durham, NC 27708, USA.

Science Translational Medicine
|April 23, 2010
PubMed

Insights

Cancer survival rates have stagnated despite decades of research. Implementing personalized medicine, guided by biomarker development in clinical trials, is crucial for significant survival improvements.

Area of Science:

  • Oncology
  • Translational Medicine
  • Biomarker Discovery

Background:

  • Despite substantial investment over 30 years, overall cancer patient survival rates show minimal improvement.
  • Current treatment strategies often lack precision, leading to incremental rather than substantial gains.

Purpose of the Study:

  • To highlight the limitations of current cancer treatment paradigms.
  • To advocate for the integration of personalized medicine principles into future clinical trial designs.
  • To emphasize the critical role of biomarker development in achieving significant advancements in cancer patient survival.

Main Methods:

  • Review of historical cancer research investment and survival outcomes.
  • Conceptual framework proposing personalized medicine as a solution.
  • Recommendation for integrating biomarker development into clinical trial design.

Main Results:

  • Analysis indicates a plateau in overall cancer survival rates.
  • Personalized medicine, focusing on right patient, right treatment, right time, is identified as key.
  • Biomarker development is proposed as essential for future progress.

Conclusions:

  • Incremental improvements in cancer survival are insufficient.
  • A paradigm shift towards personalized medicine is imperative.
  • Future clinical trials must incorporate robust biomarker development strategies to drive substantial survival gains.

More Related Videos

Automating Tumor Implantation in Zebrafish Larvae for Cancer Research and Medicine06:14

Automating Tumor Implantation in Zebrafish Larvae for Cancer Research and Medicine

Published on: September 19, 2025

Establishment and Evaluation of a Risk Prediction Model for Pathological Escalation of Gastric Low-Grade Intraepithelial Neoplasia03:05

Establishment and Evaluation of a Risk Prediction Model for Pathological Escalation of Gastric Low-Grade Intraepithelial Neoplasia

Published on: February 16, 2024

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...